NEW YORK, NY, Kallyope today announced the closing of a $236 million Series D financing round.
Kallyope, a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors. The funds will be used to advance the company's pioneering drug discovery platform, clinical trials, and pipeline of multiple programs across a broad range of therapeutic areas.
Kallyope, headquartered at the Alexandria CenterĀ® for Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about